Oncomed pharmaceuticals inc (OMED)
Income statement / Yearly
Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11
Revenue:
Revenue

44,421

38,154

25,153

-

-

-

-

-

Collaboration revenue

-

-

-

25,216

39,559

37,779

8,689

28,000

Other revenue

-

-

-

683

-

-

-

-

Collaboration revenue - related party

-

-

-

-

-

-

15,970

3,365

Grant revenue

-

-

-

-

-

-

22

44

Total revenue

-

-

-

25,899

39,559

37,779

24,681

31,409

Operating expenses:
Research and development

34,443

59,839

109,713

92,873

76,430

50,048

39,893

40,058

General and administrative

18,172

16,761

18,827

18,583

13,753

11,630

7,157

6,591

Restructuring charges

1,851

2,527

-

-

-

-

-

-

Total operating expenses

54,466

79,127

128,540

111,456

90,183

61,678

47,050

46,649

Loss from operations

-10,045

-40,973

-103,387

-85,557

-50,624

-23,899

-22,369

-15,240

Interest and other income, net

1,562

828

299

-

-

-

-

-

Interest and other income, net

-

-

-

170

105

-228

140

244

Loss before income taxes

-8,483

-40,145

-103,088

-85,387

-50,519

-24,127

-

-

Interest expense

-

-

-

-

-

-

6

38

Loss before provision for income taxes

-

-

-

-

-

-

-22,235

-15,034

Income tax provision (benefit)

-382

-1,083

14

20

-509

1,944

0

0

Net loss

-8,101

-39,062

-103,102

-85,407

-50,010

-26,071

-22,235

-15,034

Net loss per common share, basic and diluted

-0.21

-1.04

-3.14

-2.84

-1.69

-1.93

-21.30

-15.40

Shares used to compute net loss per common share, basic and diluted

38,442

37,631

32,859

30,028

29,664

13,530

1,044

976

Collaboration Revenue [Member]
Revenue

44,421

36,016

21,277

-

-

-

-

-

Other Revenue [Member]
Revenue

-

2,138

3,876

-

-

-

-

-